 Carlos Santos
Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 8 | 2022 | 85 | 4.390 |
Why?
| | Kidney Transplantation | 7 | 2022 | 153 | 3.500 |
Why?
| | Organ Transplantation | 4 | 2022 | 43 | 1.860 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 63 | 1.750 |
Why?
| | Cytomegalovirus | 5 | 2022 | 83 | 1.670 |
Why?
| | Graft Rejection | 6 | 2017 | 87 | 1.650 |
Why?
| | Transplant Recipients | 6 | 2022 | 26 | 1.480 |
Why?
| | Opportunistic Infections | 2 | 2017 | 12 | 1.170 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 123 | 1.130 |
Why?
| | Patient Readmission | 3 | 2015 | 134 | 1.060 |
Why?
| | Retrospective Studies | 15 | 2022 | 3835 | 0.980 |
Why?
| | Daptomycin | 1 | 2022 | 19 | 0.900 |
Why?
| | Staphylococcal Infections | 2 | 2016 | 183 | 0.850 |
Why?
| | Antiviral Agents | 3 | 2022 | 133 | 0.850 |
Why?
| | Inpatients | 3 | 2022 | 163 | 0.840 |
Why?
| | Immunosuppressive Agents | 4 | 2016 | 166 | 0.820 |
Why?
| | Hypoglycemia | 1 | 2020 | 18 | 0.790 |
Why?
| | Antifungal Agents | 2 | 2018 | 43 | 0.760 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 45 | 0.760 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 70 | 0.750 |
Why?
| | Electronic Health Records | 1 | 2020 | 84 | 0.730 |
Why?
| | Adult | 16 | 2022 | 9848 | 0.720 |
Why?
| | Lung Transplantation | 2 | 2016 | 11 | 0.700 |
Why?
| | Cryptococcosis | 1 | 2018 | 6 | 0.660 |
Why?
| | Humans | 28 | 2023 | 32988 | 0.640 |
Why?
| | Consensus | 1 | 2018 | 121 | 0.640 |
Why?
| | Ustilaginales | 1 | 2017 | 1 | 0.620 |
Why?
| | Yeasts | 1 | 2017 | 3 | 0.620 |
Why?
| | Dermatomycoses | 1 | 2017 | 3 | 0.620 |
Why?
| | Fungemia | 1 | 2017 | 6 | 0.620 |
Why?
| | Kidney Failure, Chronic | 2 | 2016 | 188 | 0.620 |
Why?
| | Exanthema | 1 | 2017 | 14 | 0.620 |
Why?
| | Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.610 |
Why?
| | Roseolovirus Infections | 1 | 2016 | 2 | 0.600 |
Why?
| | Endocarditis, Bacterial | 1 | 2016 | 18 | 0.600 |
Why?
| | Risk Factors | 8 | 2022 | 2762 | 0.580 |
Why?
| | Renal Insufficiency | 2 | 2019 | 22 | 0.570 |
Why?
| | United States | 6 | 2022 | 2632 | 0.560 |
Why?
| | Middle Aged | 15 | 2020 | 11219 | 0.550 |
Why?
| | Bacteremia | 1 | 2016 | 120 | 0.550 |
Why?
| | Liver Failure | 1 | 2015 | 13 | 0.540 |
Why?
| | Heart Transplantation | 1 | 2014 | 51 | 0.510 |
Why?
| | International Classification of Diseases | 1 | 2014 | 26 | 0.510 |
Why?
| | Liver Transplantation | 1 | 2015 | 112 | 0.480 |
Why?
| | Male | 17 | 2020 | 17726 | 0.480 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 434 | 0.470 |
Why?
| | Pneumonia, Viral | 1 | 2015 | 101 | 0.470 |
Why?
| | Aged | 11 | 2022 | 10542 | 0.470 |
Why?
| | Immunocompromised Host | 3 | 2017 | 54 | 0.430 |
Why?
| | Time Factors | 6 | 2019 | 1873 | 0.430 |
Why?
| | Lemierre Syndrome | 1 | 2011 | 1 | 0.410 |
Why?
| | Young Adult | 7 | 2020 | 2287 | 0.410 |
Why?
| | Proportional Hazards Models | 4 | 2016 | 387 | 0.400 |
Why?
| | Incidence | 3 | 2021 | 840 | 0.380 |
Why?
| | HIV Infections | 1 | 2018 | 1000 | 0.380 |
Why?
| | Ganciclovir | 2 | 2022 | 26 | 0.380 |
Why?
| | Multivariate Analysis | 3 | 2015 | 386 | 0.360 |
Why?
| | Hospital Mortality | 3 | 2015 | 197 | 0.360 |
Why?
| | Female | 13 | 2020 | 18423 | 0.340 |
Why?
| | Postoperative Complications | 1 | 2016 | 1117 | 0.340 |
Why?
| | Directly Observed Therapy | 1 | 2006 | 2 | 0.300 |
Why?
| | Graft Survival | 2 | 2017 | 110 | 0.290 |
Why?
| | HIV Seropositivity | 1 | 2006 | 98 | 0.290 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2006 | 144 | 0.280 |
Why?
| | Delivery of Health Care | 2 | 2023 | 166 | 0.250 |
Why?
| | Comorbidity | 2 | 2014 | 563 | 0.220 |
Why?
| | Carbapenems | 1 | 2022 | 38 | 0.220 |
Why?
| | Microbial Sensitivity Tests | 1 | 2022 | 125 | 0.220 |
Why?
| | Benchmarking | 1 | 2022 | 42 | 0.220 |
Why?
| | Drug Resistance, Bacterial | 1 | 2022 | 58 | 0.220 |
Why?
| | Virus Diseases | 1 | 2022 | 18 | 0.220 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2022 | 51 | 0.220 |
Why?
| | Vancomycin | 1 | 2022 | 57 | 0.220 |
Why?
| | Pancreas Transplantation | 1 | 2021 | 17 | 0.210 |
Why?
| | Adolescent | 3 | 2020 | 2687 | 0.210 |
Why?
| | Follow-Up Studies | 3 | 2016 | 2053 | 0.210 |
Why?
| | Medicare | 1 | 2022 | 129 | 0.210 |
Why?
| | Graft vs Host Disease | 1 | 2021 | 60 | 0.210 |
Why?
| | Rectal Prolapse | 1 | 2021 | 4 | 0.200 |
Why?
| | Pancreas | 1 | 2021 | 39 | 0.200 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 27 | 0.200 |
Why?
| | Dyspepsia | 1 | 2020 | 1 | 0.200 |
Why?
| | Helicobacter Infections | 1 | 2020 | 3 | 0.200 |
Why?
| | Helicobacter pylori | 1 | 2020 | 3 | 0.200 |
Why?
| | Drinking Water | 1 | 2020 | 4 | 0.200 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 81 | 0.190 |
Why?
| | Aged, 80 and over | 4 | 2020 | 5249 | 0.190 |
Why?
| | Cohort Studies | 2 | 2016 | 2077 | 0.190 |
Why?
| | Insulin | 1 | 2020 | 117 | 0.180 |
Why?
| | Kidney | 1 | 2021 | 219 | 0.180 |
Why?
| | Creatinine | 1 | 2019 | 59 | 0.180 |
Why?
| | Laparoscopy | 1 | 2021 | 193 | 0.170 |
Why?
| | Preoperative Period | 1 | 2019 | 71 | 0.170 |
Why?
| | Coronary Artery Bypass | 1 | 2019 | 74 | 0.170 |
Why?
| | Meningitis, Cryptococcal | 1 | 2018 | 2 | 0.170 |
Why?
| | Saccharomyces | 1 | 2017 | 1 | 0.160 |
Why?
| | Idarubicin | 1 | 2017 | 1 | 0.160 |
Why?
| | Cryptococcus | 1 | 2017 | 3 | 0.160 |
Why?
| | Amphotericin B | 1 | 2017 | 7 | 0.160 |
Why?
| | Trichosporon | 1 | 2017 | 3 | 0.160 |
Why?
| | Echinocandins | 1 | 2017 | 7 | 0.160 |
Why?
| | Lipopeptides | 1 | 2017 | 12 | 0.160 |
Why?
| | Voriconazole | 1 | 2017 | 9 | 0.160 |
Why?
| | Vidarabine | 1 | 2017 | 13 | 0.160 |
Why?
| | Cytarabine | 1 | 2017 | 13 | 0.160 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 12 | 0.160 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 13 | 0.160 |
Why?
| | Urinary Tract Infections | 1 | 2017 | 39 | 0.150 |
Why?
| | Paecilomyces | 1 | 2016 | 3 | 0.150 |
Why?
| | Fever | 1 | 2017 | 40 | 0.150 |
Why?
| | Herpesvirus 7, Human | 1 | 2016 | 2 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2017 | 48 | 0.150 |
Why?
| | Herpesvirus 6, Human | 1 | 2016 | 4 | 0.150 |
Why?
| | Lung Diseases, Fungal | 1 | 2016 | 10 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2016 | 8 | 0.150 |
Why?
| | Prognosis | 2 | 2019 | 1011 | 0.150 |
Why?
| | Dyspnea | 1 | 2016 | 39 | 0.150 |
Why?
| | Medicare Part D | 1 | 2016 | 7 | 0.150 |
Why?
| | Pharmacoepidemiology | 1 | 2016 | 5 | 0.150 |
Why?
| | Kidney Function Tests | 1 | 2016 | 28 | 0.140 |
Why?
| | Biopsy | 1 | 2017 | 277 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 128 | 0.140 |
Why?
| | Glomerular Filtration Rate | 1 | 2016 | 77 | 0.140 |
Why?
| | Genotype | 2 | 2020 | 422 | 0.130 |
Why?
| | Penile Erection | 1 | 2015 | 26 | 0.130 |
Why?
| | Florida | 1 | 2014 | 20 | 0.130 |
Why?
| | California | 1 | 2014 | 38 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 378 | 0.130 |
Why?
| | Severity of Illness Index | 2 | 2016 | 1242 | 0.130 |
Why?
| | Erectile Dysfunction | 1 | 2015 | 49 | 0.130 |
Why?
| | Brazil | 3 | 2020 | 43 | 0.130 |
Why?
| | Income | 1 | 2014 | 81 | 0.120 |
Why?
| | Databases, Factual | 1 | 2015 | 393 | 0.120 |
Why?
| | Residence Characteristics | 1 | 2014 | 228 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2021 | 4036 | 0.110 |
Why?
| | Bacterial Typing Techniques | 1 | 2011 | 12 | 0.100 |
Why?
| | Age Factors | 1 | 2014 | 932 | 0.100 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2011 | 9 | 0.100 |
Why?
| | Molecular Typing | 1 | 2011 | 9 | 0.100 |
Why?
| | Astacoidea | 1 | 2009 | 1 | 0.090 |
Why?
| | Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.090 |
Why?
| | Paragonimiasis | 1 | 2009 | 1 | 0.090 |
Why?
| | Paragonimus westermani | 1 | 2009 | 1 | 0.090 |
Why?
| | Shellfish | 1 | 2009 | 3 | 0.090 |
Why?
| | Cerebral Infarction | 1 | 2011 | 159 | 0.090 |
Why?
| | Quality of Life | 1 | 2015 | 747 | 0.090 |
Why?
| | Urban Health | 1 | 2006 | 29 | 0.070 |
Why?
| | Attitude to Health | 1 | 2006 | 116 | 0.070 |
Why?
| | Pilot Projects | 1 | 2006 | 466 | 0.070 |
Why?
| | Patient Compliance | 1 | 2006 | 200 | 0.070 |
Why?
| | Hospitalization | 1 | 2006 | 367 | 0.060 |
Why?
| | Health Facilities | 1 | 2023 | 19 | 0.060 |
Why?
| | Patients | 1 | 2023 | 35 | 0.060 |
Why?
| | Perineum | 1 | 2021 | 8 | 0.050 |
Why?
| | Tissue Donors | 1 | 2021 | 85 | 0.050 |
Why?
| | Hospitals | 1 | 2022 | 159 | 0.050 |
Why?
| | Infection Control | 1 | 2022 | 172 | 0.050 |
Why?
| | Pandemics | 1 | 2022 | 253 | 0.050 |
Why?
| | Patient Discharge | 1 | 2021 | 169 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 364 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 250 | 0.040 |
Why?
| | Prevalence | 1 | 2020 | 554 | 0.040 |
Why?
| | Logistic Models | 1 | 2019 | 474 | 0.040 |
Why?
| | Microbiological Techniques | 1 | 2016 | 10 | 0.040 |
Why?
| | Microscopy | 1 | 2016 | 15 | 0.040 |
Why?
| | Bronchoscopy | 1 | 2016 | 38 | 0.040 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 40 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1058 | 0.040 |
Why?
| | Length of Stay | 1 | 2019 | 382 | 0.040 |
Why?
| | Recurrence | 1 | 2017 | 400 | 0.040 |
Why?
| | Survival Rate | 1 | 2017 | 443 | 0.040 |
Why?
| | Midwestern United States | 1 | 2016 | 73 | 0.040 |
Why?
| | Risk | 1 | 2016 | 228 | 0.030 |
Why?
| | Risk Assessment | 1 | 2019 | 814 | 0.030 |
Why?
| | Translations | 1 | 2015 | 16 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 45 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 156 | 0.030 |
Why?
| | Personal Satisfaction | 1 | 2015 | 57 | 0.030 |
Why?
| | Language | 1 | 2015 | 87 | 0.030 |
Why?
| | Psychometrics | 1 | 2015 | 292 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2015 | 893 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 899 | 0.030 |
Why?
| | Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
| | Hemoptysis | 1 | 2009 | 9 | 0.020 |
Why?
| | Food Contamination | 1 | 2009 | 4 | 0.020 |
Why?
| | Praziquantel | 1 | 2009 | 5 | 0.020 |
Why?
| | Anthelmintics | 1 | 2009 | 10 | 0.020 |
Why?
| | Missouri | 1 | 2009 | 28 | 0.020 |
Why?
| | Tuberculosis | 1 | 2009 | 26 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 462 | 0.020 |
Why?
| | Animals | 1 | 2009 | 5371 | 0.010 |
Why?
|
|
Santos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|